Document Detail

Behavioral and biochemical evidence for a different effect of repeated administration of L-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors.
MedLine Citation:
PMID:  3431663     Owner:  NLM     Status:  MEDLINE    
The effect of repeated administration of bromocriptine and L-3,4-dihydroxyphenylalanine (L-DOPA) was studied behaviorally and biochemically in rats with a unilateral lesion of the nigrostriatal pathway. Groups of rats injected eight times with bromocriptine or L-DOPA significantly increased their contraversive circling. Rats receiving only two injections of bromocriptine did not. Animals receiving two injections of L-DOPA showed a slight but significant increase in circling. The affinity of the binding of [3H]spiperone to the dopamine receptors was unchanged by the lesion or the treatments, while the density of the binding was significantly modified. Chronic treatment with bromocriptine induced a significant decrease in the density of D2 dopamine receptors in the intact striata, while on the lesioned side, it remained unchanged. By contrast, chronic administration of L-DOPA induced a significant increase in density of the striatal dopamine receptors in the lesioned striata in addition to that caused by denervation, while the decrease on the intact side was not significant. It seems that contrary to the intact striatum, the lesioned side had a defective down-regulation mechanism in response to chronic treatment with a dopamine agonist. The results also show that L-DOPA was more potent than bromocriptine in inducing agonist supersensitivity in a denervated striatum. This may explain why chronic treatment with bromocriptine has a lesser tendency to induce dyskinesia in patients with Parkinson's disease.
C Rouillard; P J Bédard; P Falardeau; T Dipaolo
Related Documents :
9336313 - Effects of noradrenergic lesions on mptp/mpp+ kinetics and mptp-induced nigrostriatal d...
1187753 - Reversal of the 6-hydroxydopamine-induced suppression of a car by drugs facilitating ce...
24888933 - Benefits of the antioxidant and anti-inflammatory activity of etoricoxib in the prevent...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuropharmacology     Volume:  26     ISSN:  0028-3908     ISO Abbreviation:  Neuropharmacology     Publication Date:  1987 Nov 
Date Detail:
Created Date:  1988-03-09     Completed Date:  1988-03-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0236217     Medline TA:  Neuropharmacology     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1601-6     Citation Subset:  IM    
Department of Anatomy, Faculty of Medicine, Laval University, Québec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Behavior, Animal / drug effects*
Benserazide / pharmacology
Bromocriptine / pharmacology*
Corpus Striatum / drug effects,  metabolism*
Levodopa / pharmacology*
Receptors, Dopamine / drug effects*
Spiperone / diagnostic use
Reg. No./Substance:
0/Levodopa; 0/Receptors, Dopamine; 25614-03-3/Bromocriptine; 322-35-0/Benserazide; 749-02-0/Spiperone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differential modification of morphine and methadone dependence by interferon alpha.
Next Document:  Comparison of ketamine, physical restraint, halothane and pentobarbital: lack of influence on seroto...